SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-027629
Filing Date
2024-02-08
Accepted
2024-02-08 08:27:01
Documents
16
Period of Report
2024-02-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d750834d8k.htm   iXBRL 8-K 27002
2 EX-99.1 d750834dex991.htm EX-99.1 9969
6 GRAPHIC g750834g0208065252412.jpg GRAPHIC 7597
  Complete submission text file 0001193125-24-027629.txt   178409

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA acrv-20240207.xsd EX-101.SCH 2837
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE acrv-20240207_lab.xml EX-101.LAB 18736
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acrv-20240207_pre.xml EX-101.PRE 11698
17 EXTRACTED XBRL INSTANCE DOCUMENT d750834d8k_htm.xml XML 3758
Mailing Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472
Business Address 480 ARSENAL WAY, SUITE 100 WATERTOWN MA 02472 617-207-8979
Acrivon Therapeutics, Inc. (Filer) CIK: 0001781174 (see all company filings)

IRS No.: 825125532 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41551 | Film No.: 24606960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)